ACIU (AC Immune) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 27, 2026)


ACIU AC Immune SA ACIU
26 GF Score
Price $2.56
GF Value $0.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AC Immune Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

AC Immune's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ACIU vs TRDA, MGNX, SABS: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, AC Immune's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AC Immune Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AC Immune's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where AC Immune's Margin of Safety % (DCF FCF Based) falls into.


ACIU
26GF Score
AC Immune SA ACIU
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AC Immune (ACIU) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be overvalued. The current stock price of $2.56 is trading 241.3% above its estimated GF Value™ of $0.75. GuruFocus considers AC Immune to be Significantly Overvalued.

Key valuation signals for ACIU:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $0.75 vs. price of $2.56 (241.3% above fair value)
  • GF Score™: 26/100 with 6 warning signs

No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AC Immune Business Description

Other Exchanges IMR:Germany
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
26GF Score

Get the complete analysis for ACIU

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.56
Price
$0.75
GF Value